title: Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients.
abstract: The colorectal carcinoma (CRC)-associated GA733 antigen (also known as CO17-1A, KS1-4, KSA or EpCAM) has been the target of a phase II/III randomized trial of passive immunotherapy with monoclonal antibody CO17-1A and phase I active immunotherapy trials with polyclonal anti-idiotypic antibodies mimicking the CO17-1A or GA733 epitope on the antigen. The CO17-1A antigen was molecularly cloned and the extracellular domain expressed in baculovirus (BV) GA733-2E. Whereas, anti-idiotypic antibody mimics a single epitope on the antigen, BV GA733-2E expresses multiple potentially immunogenic epitopes. In animals, the immunogenicity of BV GA733-2E in aluminum hydroxide was superior to that of anti-idiotype in the same adjuvant. Here, we compared the immunogenicity of anti-idiotypic antibody and GA733-2E antigen in CRC patients. These studies indicate that the antigen is superior to the anti-idiotype antibody in inducing humoral and cellular immunity in CRC patients.
authors: The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
authors: B
authors: B
authors: Birebent
authors: R
authors: R
authors: Somasundaram
authors: E
authors: E
authors: Purev
authors: W
authors: W
authors: Li
authors: E
authors: E
authors: Mitchell
authors: D
authors: D
authors: Hoey
authors: E
authors: E
authors: Bloom
authors: M
authors: M
authors: Mastrangelo
authors: H
authors: H
authors: Maguire
authors: D T
authors: DT
authors: Harris
authors: L
authors: L
authors: Staib
authors: H
authors: H
authors: Braumuller
authors: C
authors: C
authors: Leeser
authors: N
authors: N
authors: Kuttner
authors: H G
authors: HG
authors: Beger
authors: D
authors: D
authors: Herlyn
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use*; D019496:Cancer Vaccines; D015815:Cell Adhesion Molecules / Q000008:administration & dosage / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D000071858:Epithelial Cell Adhesion Molecule; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007167:Immunotherapy; D018716:Molecular Mimicry; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015815:Cell Adhesion Molecules; D000071858:Epithelial Cell Adhesion Molecule; D011994:Recombinant Proteins